Clinical Trial Update: Zanubrutinib Treatment in Patients With IgM Monoclonal Gammopathy and Antri-MAG Related Polyneuropathy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial investigating zanubrutinib for IgM monoclonal gammopathy with anti-MAG-related polyneuropathy is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anti-mag Neuropathy
• Monoclonal Gammopathy of Undetermined Significance

Drugs mentioned

• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: UMC Utrecht | Conditions: Monoclonal Gammopathy of Uncertain Significance | Phase 2 | Status: RECRUITING